Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn

Table of Contents

November 01, 1994; Volume 22,Issue 6
  • You have access
    Solvolysis of butadiene monoxide.
    I Linhart
    Drug Metabolism and Disposition November 1994, 22 (6) 820-821;
  • You have access
    Propranolol disposition in the single-pass isolated, perfused rat liver in the presence and absence of insulin and glucagon.
    H A Semple and F Xia
    Drug Metabolism and Disposition November 1994, 22 (6) 822-826;
  • You have access
    Theophylline N-demethylations as probes for P4501A1 and P4501A2.
    M A Sarkar and B J Jackson
    Drug Metabolism and Disposition November 1994, 22 (6) 827-834;
  • You have access
    Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.
    F P Lacreta, J M Brennan, T C Hamilton, R F Ozols and P J O'Dwyer
    Drug Metabolism and Disposition November 1994, 22 (6) 835-842;
  • You have access
    Pharmcokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis.
    E Ezan, P Carde, J Le Kerneau, T Ardouin, F Thomas, F Isnard, E Deschamps de Paillette and J M Grognet
    Drug Metabolism and Disposition November 1994, 22 (6) 843-848;
  • You have access
    Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals.
    M Jurima-Romet, K Crawford, T Cyr and T Inaba
    Drug Metabolism and Disposition November 1994, 22 (6) 849-857;
  • You have access
    A comprehensive evaluation of the vial equilibration method for quantification of the metabolism of volatile organic chemicals. Trichloroethylene.
    C Kim, R O Manning, R P Brown and J V Bruckner
    Drug Metabolism and Disposition November 1994, 22 (6) 858-865;
  • You have access
    Urinary metabolites of (R),(R)-labetalol.
    K B Alton, T M Chan and B N Pramanik
    Drug Metabolism and Disposition November 1994, 22 (6) 866-872;
  • You have access
    Pharmacokinetics and metabolism of cyclosporin G in humans.
    J B Mangold, H F Schran and F L Tse
    Drug Metabolism and Disposition November 1994, 22 (6) 873-879;
  • You have access
    The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans.
    J F Denissen, B A Grabowski, M K Johnson, S A Boyd, J T Uchic, H Stein, S Cepa and P Hill
    Drug Metabolism and Disposition November 1994, 22 (6) 880-888;
  • You have access
    Species differences in the induction of hepatic microsomal carboxylesterases caused by dietary exposure to di(2-ethylhexyl)phthalate, a peroxisome proliferator.
    M Hosokawa, K Hirata, F Nakata, T Suga and T Satoh
    Drug Metabolism and Disposition November 1994, 22 (6) 889-894;
  • You have access
    Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.
    L M Shaw, H S Bonner and D Q Brown
    Drug Metabolism and Disposition November 1994, 22 (6) 895-902;
  • You have access
    Hepatic metabolism of spironolactone. Production of 3-hydroxy-thiomethyl metabolites.
    L E Los, S M Pitzenberger, H G Ramjit, A B Coddington and H D Colby
    Drug Metabolism and Disposition November 1994, 22 (6) 903-908;
  • You have access
    Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
    Y Masubuchi, S Hosokawa, T Horie, T Suzuki, S Ohmori, M Kitada and S Narimatsu
    Drug Metabolism and Disposition November 1994, 22 (6) 909-915;
  • You have access
    In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes.
    T Hasegawa, K Hara, T Kenmochi and S Hata
    Drug Metabolism and Disposition November 1994, 22 (6) 916-921;
  • You have access
    Glucuronidation of N-acetylbenzidine by human liver.
    S R Babu, V M Lakshmi, T V Zenser and B B Davis
    Drug Metabolism and Disposition November 1994, 22 (6) 922-927;
  • You have access
    Identification of 9,13-dicis-retinoic acid as a major plasma metabolite of 9-cis-retinoic acid and limited transfer of 9-cis-retinoic acid and 9,13-dicis-retinoic acid to the mouse and rat embryos.
    G Tzimas, J O Sass, W Wittfoht, M M Elmazar, K Ehlers and H Nau
    Drug Metabolism and Disposition November 1994, 22 (6) 928-936;
  • You have access
    Metabolism of the proestrogenic pesticide methoxychlor by hepatic P450 monooxygenases in rats and humans. Dual pathways involving novel ortho ring-hydroxylation by CYP2B.
    S S Dehal and D Kupfer
    Drug Metabolism and Disposition November 1994, 22 (6) 937-946;
  • You have access
    Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
    K S Lown, J C Kolars, K E Thummel, J L Barnett, K L Kunze, S A Wrighton and P B Watkins
    Drug Metabolism and Disposition November 1994, 22 (6) 947-955;
  • You have access
    Mechanism of covalent adduct formation of diclofenac to rat hepatic microsomal proteins. Retention of the glucuronic acid moiety in the adduct.
    A Kretz-Rommel and U A Boelsterli
    Drug Metabolism and Disposition November 1994, 22 (6) 956-961;
  • You have access
    Identification of hepatocytes as the major locus of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced CYP1-related P450s, TCDDAA and TCDDAHH, in chick embryo liver.
    L Paroli, C Lee and A B Rifkind
    Drug Metabolism and Disposition November 1994, 22 (6) 962-968;
  • You have access
    Increased cosedimentation of cytosolic glutathione S-transferases with microsomal fractions prepared from frozen rat liver.
    A E Cribb, G P Griffin, S P Spielberg, T H Rushmore, N Chauret and D A Nicoll-Griffith
    Drug Metabolism and Disposition November 1994, 22 (6) 969-972;
  • You have access
    Tissue distribution and stereoselectivity of remacemide-glycine hydrolase.
    H Heyn, Y G Bankmann and M W Anders
    Drug Metabolism and Disposition November 1994, 22 (6) 973-974;
  • You have access
    Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.
    S D Hall, M A Hamman, A E Rettie, L C Wienkers, W F Trager, M Vandenbranden and S A Wrighton
    Drug Metabolism and Disposition November 1994, 22 (6) 975-978;
Back to top
PreviousNext

In this issue

Drug Metabolism and Disposition
Vol. 22, Issue 6
1 Nov 1994
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
  • Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes
  • DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
  • In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model
  • THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics